Taevas
Commercial, regulatory, and competitive intelligence for life sciences and consumer health companies expanding globally.
Market intelligence is the systematic gathering, analysis, and interpretation of data about a market — its size, growth, competitive dynamics, regulatory environment, and commercial landscape — to enable informed strategic decisions.
At Taevas, we go beyond desk research. Our intelligence combines primary expert interviews, proprietary databases, regulatory filings, and commercial analytics to give you a complete picture of your opportunity — before you commit capital or resources.
Board-ready intelligence that de-risks decisions and accelerates market entry.
KOL interviews, regulator consultations, channel partner dialogues
Regulatory filings, clinical databases, commercial analytics
TAM/SAM/SOM projections, scenario planning, sensitivity analysis
Go/no-go criteria, market prioritisation, launch sequencing
Six interconnected dimensions of intelligence — each rigorous on its own, transformative together.
TAM, SAM, and SOM modelling with 5-year growth projections across therapy areas and geographies.
Approval pathways, timelines, and compliance frameworks across FDA, EMA, CDSCO, and 40+ global markets.
Pipeline benchmarking, product positioning, SWOT analysis, and whitespace identification.
Pricing benchmarks, reimbursement landscape, market access pathways, and launch readiness assessment.
Market prioritisation based on demand signals, competitive intensity, and regulatory ease-of-entry.
Interactive visualisations synthesising intelligence into executive-ready decision frameworks.
A structured four-stage process that balances speed with rigour — typically complete in 4–6 weeks.
We align on objectives, geographies, therapy areas, and the specific business questions that need answering.
A 30–45 minute scoping call establishes the intelligence framework — ensuring every subsequent research hour is focused on decisions that matter.
Intelligence calibrated to the unique regulatory, commercial, and competitive dynamics of your sector.
From branded generics to biologics, we cover the full pharmaceutical value chain — clinical pipeline tracking, patent cliff analysis, and reimbursement modelling across regulated and emerging markets.
Deep-dive intelligence across all major pharmaceutical, medtech, and consumer health markets worldwide.
India · China · Japan · South Korea · Australia · Indonesia · Thailand · Vietnam · Philippines
Germany · France · UK · Italy · Spain · Netherlands · Switzerland · Poland · Sweden
United States · Canada · Brazil · Mexico · Colombia · Argentina · Chile
UAE · Saudi Arabia · Turkey · Israel · Egypt · Qatar
South Africa · Nigeria · Kenya · Ethiopia · Morocco
Bangladesh · Sri Lanka · Pakistan · Nepal · Myanmar
Comprehensive deliverables designed for board-level decisions — not just background reading.
TAM/SAM/SOM with 5-year projections, segmented by product type, end user, and geography.
Profiling of top 10–15 players with pipeline, financials, positioning, and SWOT analysis.
Step-by-step approval guide, typical timelines, required dossiers, and local partner requirements.
Benchmark pricing across channels, reimbursement eligibility, and HTA decision landscape.
Prioritised strategy with recommended partnerships, channels, and launch sequencing.
Key opinion leaders, payer organisations, and the distributor ecosystem across target markets.
Interactive data visualisation summarising findings for C-suite and board presentations.
Post-delivery support to clarify findings, run scenario analyses, or refine recommendations.
Whether you're validating a new geography or preparing a board-level market entry case — we have a format that fits.
Evaluating new market entry, product launches in new geographies, or acquisitions requiring deep commercial due diligence.
Conducting commercial due diligence, validating market size assumptions, or assessing competitive moats before committing capital.
Seeking investor-grade market data to underpin fundraising narratives, identify first-mover opportunities, or prioritise expansion.
Understanding sector landscapes, benchmarking policy environments, and identifying foreign investment opportunities in health and life sciences.
Translating academic research into commercial potential assessments, technology transfer opportunities, and licensing strategy.
White-label intelligence support for strategy and management consulting firms advising clients across life sciences markets.
Our analysts work exclusively in pharma, medtech, and consumer health. Every report reflects deep domain expertise — not generic research methodology applied to healthcare.
We don't just aggregate public data. Every engagement includes primary interviews with regulators, KOLs, payers, and channel partners — intelligence you can't Google.
Our network spans India, Southeast Asia, MENA, and Sub-Saharan Africa — markets that generic firms cover superficially but where the greatest growth opportunities exist.
We write for decision-makers, not archives. Every report includes a clear recommendation. Our readout sessions are structured for board discussions, not just information transfer.
Rapid-response turnarounds of 2–4 weeks for focused engagements — without sacrificing the rigour of primary research and expert validation.
Our 30-day Q&A window, ongoing subscriptions, and retainer models mean we're a long-term intelligence partner — not a one-off vendor.
“Taevas gave us the confidence to enter the Indian market two quarters ahead of schedule. Their intelligence didn't just answer our questions — it showed us the questions we hadn't thought to ask.”
Market intelligence is the starting point. Pair it with our complementary services to go from insight to action.
From regulatory pathway mapping to full dossier preparation and submission management across global markets.
Shortlisting, evaluating, and connecting you with validated in-market partners, distributors, and licensing candidates.
Optimise launch pricing, reimbursement positioning, and access pathways to maximise commercial success from day one.
Scientific communication strategy, publication planning, and structured KOL engagement programmes for new market entrants.
Investor-grade commercial assessments for M&A, licensing deals, or fundraising — with rapid turnaround for live transactions.
Monthly or quarterly market monitoring — competitive signals, regulatory updates, and commercial developments as a managed service.
Tell us your target market and product category. We'll scope a custom intelligence project within 48 hours.